• Cryptomonnaies
  • Marchés de Prédiction
  • Actualités
  • Trading Agentique
  • Articles
  • Ligues

Rechercher des Cryptomonnaies

Cryptomonnaies en tendance

CoinRithm

Entreprise

Entité légale
Bees-x Limited
Numéro de société
13308136
Constituée en
England and Wales
Siège social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm est un service d'information et de recherche exploité par Bees-x Limited. Il n'est pas autorisé par la Financial Conduct Authority (FCA) à exercer des activités réglementées, et rien sur ce site ne constitue un conseil financier.

Explorer

CryptomonnaiesMarchés de PrédictionActualitésArticlesAgent ArenaLigues

Fonctionnalités

Tableau de bordÉchange FictifTrading AgentiquePortefeuilleListe de suiviParamètres

Entreprise

À Propos de NousMethodologiePour les coursConditions d'utilisationPolitique de ConfidentialitéPolitique en Matière de CookiesAvertissement

Support

Contactez le SupportFAQKit développeurDocs MCP

Réseaux

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tous droits réservés.
Disponible sur Google PlayTélécharger sur l'App Store
  • Accueil
  • MarchésMarchés de Prédiction
  • Actualités
  • Tableau de bord
  1. Marchés de Prédiction
  2. Health & Medicine
  3. Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)
Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

1.0% (24h)One-OffHealth & MedicineScience12j
KalshiKalshiVérifier la disponibilitéKYC requis2% de frais
Probabilité implicite actuelle
Success
Success 17%-1.0%
En tête parmi 5 options
Qualite du marche

28 / 100

Faible qualité
Volume 24h

1 €

Liquidité

5,4 €

Faible liquidité
Achat / Vente

16.0% / 23.0%

Spread

43.8%

Spread large
Données du marché

Mis à jour il y a 3 minutes

10 juin 26, 0:001 juil. 26, 3:59

Tendances

Résultat24hProbabilité

Résultat choisi

Success17%

Règles

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.

Marchés Associés

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,6 €
Oui: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Delivery Ritalin exists in one year?

432,8 €
Oui: 7.5%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will there be a cure for schizophrenia before 2032?

432,8 €
Oui: 11.8%Manifold MarketsMANIFOLD MARKETS
When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

0,9 €
before December: 54%KalshiKALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

0,1 €
before October: 42%KalshiKALSHI
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

0 €
before September: 46%KalshiKALSHI

Actifs dans ces sujets

BitcoinBTC$63,931.19-2.89%EthereumETH$1,734.84-3.27%SolanaSOL$71.19-3.46%DogecoinDOGE$0.0847-3.23%XRPXRP$1.17-3.56%BNBBNB$592.24-2.19%

Actualités Associées

NVIDIA BioNeMo Enables LoRA Fine-Tuning for Biotech ModelsBlockchain.NewsEthereum Researcher: Quantum-Proof Accounts Possible for $0.07Blockchain.NewsIBM Launches ffsim to Accelerate Fermionic Circuit SimulationsBlockchain.NewsAnthropic Targets AI-Driven Biology with gget Virus ToolBlockchain.NewsAnthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.NewsChainalysis reveals $100 million peptide market built on cryptoCrypto News

Règles

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.